AlphAIalphai — Financial news for AI agents
SEC EDGARSEP 21 min read$RVMD

Kim Lorence H. sold $11.4M of RVMD (indirect holdings)

Kim Lorence H. sold 56,000 indirectly-held shares of Revolution Medicines, Inc. (RVMD) at an average of $203.24 ($200.56–$206.15, $11.38M total) across 7 trades on 2026-08-31 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kim Lorence H.
Published Sep 2, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 2, 2026, 9:07 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$RVMD
Bearish
medium confidence
Mentioned
$RVMD
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RVMDBearishLow
01

Why it matters

The director's $11.4M sale is the first public disclosure of this transaction, providing fresh data for traders.

02

Market read

Direct insider sell of a sizable amount may influence short‑term price action and sentiment in the biotech space.

03

What to watch

Potential upcoming clinical data or financing events not disclosed may be driving the sell.

Relevance 6/10Novelty 7/10Timing: post‑market filing on 2026‑09‑02

Background

SEC Form 4 filing discloses insider transactions; required to be reported promptly.

Company-level read

Ticker impact

$RVMDBearishMedium confidence
Context

Director Kim Lorence H. sold 56,000 shares for $11.4M via a 10b5‑1 plan on 2026‑08‑31.

Expected impact

Potential short‑term pressure on RVMD, modest downside of 2‑4% in the next few days.

Evidence & confidence

Large dollar amount relative to typical insider trades and use of a pre‑arranged plan suggest a material move, but no accompanying corporate event.

Market effects

Sector

Biotech sector may see slight bearish tilt as insider sell adds to perception of risk.

Regional

US biotech investors may adjust exposure; limited broader market effect.

Global

Minimal global impact beyond RVMD shareholders.

Counterpoint

What could challenge this read

The sale could be routine portfolio diversification, not a red flag.

Key entities

  • Company
    Revolution Medicines, Inc.

    Biotech firm developing oncology therapies, ticker RVMD.

  • Insider
    Kim Lorence H.

    Director of Revolution Medicines, executing a 10b5‑1 sell plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RVMD insider trading history →

Related articles

SEP 4
$RVMDHighAI 8/10

Michael Osterholm Says He's Staying Four More Years as Public Health's Systems Buckle — BigGo Finance

Revolution Medicines' FDA-approved cancer drug, divarasib and razabi, targets RAS protein, previously deemed undruggable. CEO Mark Goldsmith bet the company on this target, leading to a successful Phase 3 trial. Michael Osterholm, 73, delayed retirement to address public health challenges, launching the Vaccine Integrity Project. David Baker, Nobel laureate, focuses on designing novel proteins and mentoring scientists.

finance.biggo.com2 min
SEP 3
$RVMDHighAI 9/10

Daraxonrasib shrinks tumours in one-third of lung cancer patients

Revolution Medicines Inc. (RVMD) reported that its experimental drug daraxonrasib shrank tumors in 33% of advanced lung cancer patients in a Phase 1/2 trial, with symptom improvements. The study, published in the New England Journal of Medicine, involved 136 patients with RAS gene mutations. The drug targets multiple RAS mutations and showed a median response duration of 11.5 months. Side effects were common, with rash, diarrhea, and nausea affecting many patients. The company is now conducting

mugglehead.com2 min
SEP 3
$RVMDMedAI 8/10

RevMed’s newly approved Rasonque could ‘hold up’ in non-small cell lung cancer

Revolution Medicines (RVMD) presented updated Phase 1/2 trial data for Rasonque in non-small cell lung cancer (NSCLC), showing a 42% overall response rate, 8.3-month median progression-free survival, and 16-month median overall survival. Truist Securities noted the results support RVMD's Phase 3 lung cancer study. Rasonque was recently FDA-approved for pancreatic cancer, with Phase 3 results expected in December 2027 for NSCLC.

biospace.com2 min
SEP 3
$RVMDMedAI 8/10

NEJM publishes daraxonrasib NSCLC data supporting Phase III program

Revolution Medicines (RVMD) published Phase I/II data in NEJM showing daraxonrasib's antitumor activity in RAS-mutant NSCLC. The study reported a 42% response rate and 8.3-month median progression-free survival. The company is advancing the drug in a Phase III trial. Daraxonrasib was recently approved for pancreatic cancer, marking the company's first commercial product.

allsci.com2 min
SEP 2
$RVMDMedAI 9/10

RVMD Shares React as Phase 1/2 RASONQUE Data Published in NEJM

Revolution Medicines (RVMD) announced the publication of Phase 1/2 trial results for RASONQUE in the New England Journal of Medicine. The data showed promising efficacy and safety in treating advanced RAS mutant NSCLC. The company has a market cap of $44.85 billion and is currently unprofitable, with a high Price-to-Sales ratio of 70.5x. Insider activity shows significant selling, while guru ownership trends are mixed.

gurufocus.com3 min